Idexx Laboratories INC IDEXX LABORATORIES ORD SHS
Idexx Laboratories INC IDEXX LABO.../ US45168D1046 /
0J8P
28/06/2024 20:03:11
|
Diferencia
-2.69
|
Volumen |
Bid- |
Ask- |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
490.46USD
|
-0.55%
|
82,177 Volumen de negocios: 40.59 millones |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
40.24 mil millonesUSD |
- |
47.91 |
Descripción de negocio
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 7,000 people and offers products to customers in more than 175 countries.
Consejo de gestión & Consejo de supervisión
CEO |
Jay Mazelsky |
Consejo de gestión |
Brian P. McKeon, Irene Chang Britt, Michael Lane, James F. Polewaczyk, Martin Smith, Sharon E. Underberg, Michael P. Johnson, Kerry Bennett, Mike Erickson, George J. Fennell, Ken Grady, John Hart, Dan Janson, Michael Schreck, Murthy Yerramilli |
Consejo de supervisión |
Lawrence D. Kingsley, Bruce L. Claflin, Daniel M. Junius, Dr. Asha S. Collins, Dr. Sophie V. Vandebroek, Dr. Stuart M. Essig, Jay Mazelsky, Jonathan W. Ayers, M. Anne Szostak, Sam Samad, Irene Chang Britt |
Datos de la empresa
Nombre: |
IDEXX Laboratories Inc. |
Dirección: |
One IDEXX Drive,Westbrook, Maine 04092, USA |
Teléfono: |
+1-207-556-0300 |
Fax: |
+1-207-556-4346 |
E-mail: |
-
|
Internet: |
www.idexx.com |
Industria: |
Biotechnology |
Sector: |
Biotechnology |
Subsector: |
Biotechnology |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
57.24% |
Fecha de OPI: |
21/06/1991 |
Calendario de la empresa
CW 33 | 15/08/2024
General Shareholder Meeting
|